• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cilostazol-based dual anti-platelet agents for Asian patients: An updated network meta-analysis
Antiplatelet therapy, including aspirin, has been used for the secondary prevention of non-cardioembolic ischemic stroke [1]. Because patients who have a higher risk of recurrent stroke need antiplatelet agents with higher efficacy than aspirin, dual antiplatelet therapy (DAPT) has been used in cases requiring higher efficacy, such as the acute stage of stroke or high-risk patients [2]. However, DAPT is notably associated with an increased risk of bleeding like a two-edged sword [3]. Aspirin plus clopidogrel is recommended for a few weeks after acute ischemic stroke, preventing bleeding risk from not exceeding the power of...
Source: Journal of the Neurological Sciences - October 8, 2022 Category: Neurology Authors: Seung Jin Jung, Sung Ryul Shim, Bum Joon Kim, Jin-Man Jung Source Type: research

Cilostazol improves endothelial function in patients with ischemic stroke: A randomized controlled single-center study with flow-mediated dilation technique
Recent CSPS.com study has shown the benefit of adding cilostazol on aspirin or clopidogrel for secondary stroke prevention [1]. Because a pleiotropic effect other than its anti-platelet effect such as vasodilatation and anti-atherosclerosis effect may underlie the effect [1], we examined the effects of adding cilostazol on clopidogrel on endothelial function in flow-mediated vasodilation (FMD) technique.
Source: Journal of the Neurological Sciences - June 8, 2022 Category: Neurology Authors: Yuka Shirai, Sono Toi, Utako Adachi, Yukiko Tsutsumi, Kazuo Kitagawa Source Type: research

Cilostazol uncovers covert atrial fibrillation in non-cardioembolic stroke
We hypothesized that administration of cilostazol may clarify the occult atrial fibrillation (AF) during hospitalization in mild stroke patients, who has no history of AF.
Source: Journal of the Neurological Sciences - March 20, 2020 Category: Neurology Authors: Junya Aoki, Yasuyuki Iguchi, Takao Urabe, Hiroshi Yamagami, Kenichi Todo, Shigeru Fujimoto, Koji Idomari, Nobuyuki Kaneko, Takeshi Iwanaga, Tadashi Terasaki, Ryota Tanaka, Nobuaki Yamamoto, Akira Tsujino, Koichi Nomura, Koji Abe, Masaaki Uno, Yasushi Okad Source Type: research

Two young stroke patients associated with regular intravenous immunoglobulin (IVIg) therapy
We recently experienced 2 young adult patients who developed ischemic stroke after regular intravenous immunoglobulin (IVIg) therapy for agammaglobulinemia with diagnosis of common variable immunodeficiency (CVID) in their childhood. Patient 1 was 26-year-old woman, who developed Wallenberg's syndrome 6days after the last IVIg therapy, but had no further stroke recurrence with cilostazol later. Patient 2 was 37-year-old man, who developed recurrent cerebral infarction in the territory of bilateral lenticulostriate branches like branch atheromatous disease (BAD) several days after the IVIg therapy.
Source: Journal of the Neurological Sciences - December 2, 2015 Category: Neurology Authors: Yumiko Nakano, Takeshi Hayashi, Kentaro Deguchi, Kota Sato, Nozomi Hishikawa, Toru Yamashita, Yasuyuki Ohta, Yoshiki Takao, Tomohiro Morio, Koji Abe Source Type: research